Bandera Partners LLC Acquires Shares of 1,673,108 biote Corp. (NASDAQ:BTMD)

Bandera Partners LLC acquired a new stake in shares of biote Corp. (NASDAQ:BTMDFree Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,673,108 shares of the company’s stock, valued at approximately $11,310,000. biote comprises about 4.8% of Bandera Partners LLC’s investment portfolio, making the stock its 8th biggest position.

Several other institutional investors also recently bought and sold shares of BTMD. Millennium Management LLC bought a new position in biote during the 2nd quarter valued at about $445,000. Creative Planning bought a new position in biote during the 2nd quarter valued at about $44,000. RiverPark Advisors LLC lifted its stake in biote by 229.3% during the 1st quarter. RiverPark Advisors LLC now owns 135,273 shares of the company’s stock valued at $837,000 after acquiring an additional 94,188 shares during the period. Boston Partners bought a new position in biote during the 1st quarter valued at about $5,788,000. Finally, Citigroup Inc. bought a new position in biote during the 1st quarter valued at about $69,000. 22.97% of the stock is owned by hedge funds and other institutional investors.

biote Price Performance

Shares of NASDAQ:BTMD traded up $0.07 during trading on Monday, hitting $5.04. The company’s stock had a trading volume of 25,129 shares, compared to its average volume of 110,114. The company has a 50-day moving average of $5.18 and a 200-day moving average of $5.70. biote Corp. has a 12 month low of $2.75 and a 12 month high of $8.22. The firm has a market cap of $366.71 million, a price-to-earnings ratio of -23.00 and a beta of 0.76.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Roth Mkm restated a “buy” rating and set a $12.00 target price on shares of biote in a research note on Monday, August 14th. TD Cowen lowered their price objective on shares of biote from $12.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 15th.

Check Out Our Latest Stock Report on BTMD

biote Profile

(Free Report)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements.

Featured Articles

Want to see what other hedge funds are holding BTMD? Visit to get the latest 13F filings and insider trades for biote Corp. (NASDAQ:BTMDFree Report).

Institutional Ownership by Quarter for biote (NASDAQ:BTMD)

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with's FREE daily email newsletter.